

Deepesh P Lad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8978607/publications.pdf>

Version: 2024-02-01

124
papers

24,102
citations

471371

17
h-index

23514

111
g-index

127
all docs

127
docs citations

127
times ranked

40550
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
2	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
3	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
4	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
5	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	3.4	1,691
6	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553.	3.4	1,260
7	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
8	Global Burden of Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1221.	3.4	398
9	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
10	Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. <i>Occupational and Environmental Medicine</i> , 2020, 77, 151-159.	1.3	64
11	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
12	Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. <i>Leukemia and Lymphoma</i> , 2013, 54, 1012-1019.	0.6	42
13	Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. <i>Leukemia and Lymphoma</i> , 2015, 56, 2424-2428.	0.6	39
14	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
15	Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. <i>Annals of Hematology</i> , 2020, 99, 57-63.	0.8	34
16	Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQâ€“C30 and QLQâ€“CLL17 questionnaire. <i>European Journal of Haematology</i> , 2020, 105, 755-762.	1.1	24
17	Cost of Treatment of Multiple Myeloma in a Public Sector Tertiary Care Hospital of North India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 25-31.	0.3	22
18	Evaluating the role of Tregs in the progression of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2134-2142.	0.6	20

#	ARTICLE	IF	CITATIONS
19	Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 261-267.	0.3	19
20	AYA-Myeloma: Real-World, Single-Center Experience Over Last 5 Years. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 120-124.	0.7	18
21	Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 183-189.e1.	0.2	17
22	Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019, 54, 2088-2095.	1.3	16
23	Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients. <i>International Journal of Dermatology</i> , 2018, 57, 332-338.	0.5	15
24	Regulatory T-cells drive immune dysfunction in CLL. <i>Leukemia and Lymphoma</i> , 2018, 59, 486-489.	0.6	15
25	Analysis of Clinical Profile and Outcome of Tuberculosis in Patients with Acute Leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 430-442.	0.3	15
26	Chronic Lymphocytic Leukemia: Real-World Data From India. <i>JCO Global Oncology</i> , 2020, 6, 866-872.	0.8	15
27	TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India. <i>BMC Gastroenterology</i> , 2021, 21, 327.	0.8	15
28	Therapeutic whole blood exchange in the management of methaemoglobinemia: Case series and systematic review of literature. <i>Transfusion Medicine</i> , 2020, 30, 231-239.	0.5	13
29	Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 15-21.	0.3	11
30	Complications and management of coagulation disorders in leukemia patients. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2017, Volume 7, 61-72.	1.2	11
31	Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e685-e690.	0.2	10
32	Danazol increases T regulatory cells in patients with aplastic anemia. <i>Hematology</i> , 2018, 23, 496-500.	0.7	9
33	Ponatinib-induced lamellar ichthyosis-like eruption. <i>International Journal of Dermatology</i> , 2020, 59, e156-e157.	0.5	9
34	How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 605-615.	0.3	9
35	Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival. <i>Leukemia and Lymphoma</i> , 2020, 61, 1512-1515.	0.6	9
36	Necrotising Ulcerative Gingivitis: A Rare Manifestation of Pseudomonas Infection. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 578-580.	0.3	8

#	ARTICLE	IF	CITATIONS
37	Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1102-1104.	0.6	8
38	Carfilzomib-induced thrombotic microangiopathy: A case based review. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, , .	0.6	8
39	Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression. <i>Blood Research</i> , 2020, 55, 131-138.	0.5	8
40	Establishment of a comprehensive chronic lymphocytic leukemia clinic at a tertiary referral center in India. <i>Blood Advances</i> , 2018, 2, 33-34.	2.5	7
41	Reduced Dose Ibrutinib Due to Financial Toxicity in CLL. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 260-264.	0.3	7
42	Variables affecting the presence of mesenchymal stromal cells in peripheral blood and their relationship with apheresis products. <i>British Journal of Haematology</i> , 2020, 189, 772-776.	1.2	7
43	Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India. <i>Blood Cancer Journal</i> , 2022, 12, 2.	2.8	7
44	Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 626-634.	0.2	7
45	FDG PET/CT in the staging and follow-up of primary cardiac "T" cell lymphoma presenting as hypertrophic cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , 2016, 23, 581-584.	1.4	6
46	Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 273-277.	0.3	6
47	Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 584-586.	0.3	6
48	Immune Thrombocytopenia is Still the Commonest Diagnosis on Consultative Hematology. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 352-356.	0.3	6
49	Adolescent and Young Adult Chronic Myeloid Leukemia in Real-World Settings: Experience from a Tertiary Care Institute in Northern India. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 94-97.	0.7	6
50	Aberrant expression of cytokines in polycythemia vera correlate with the risk of thrombosis. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 89, 102565.	0.6	6
51	Chronic Lymphocytic Leukemia: Inception to Cure: Are We There?. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2013, 29, 1-10.	0.3	5
52	Peri-anal Paraneoplastic Pemphigus heralding the relapse of follicular lymphoma and its successful management by Rituximab: A short correspondence. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 519-521.	0.3	5
53	Invasive Fungal Infections in Acute Promyelocytic Leukemia on Dual Differentiating Agents: Real World Data. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 466-468.	0.3	5
54	Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 68-77.	0.3	5

#	ARTICLE	IF	CITATIONS
55	Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting. <i>Leukemia and Lymphoma</i> , 2021, 62, 3271-3277.	0.6	5
56	Pyrexia, Lung nodules, Granulomas: Pulmonary Lymphomatoid Granulomatosis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 418-421.	0.3	4
57	Bullous Pyoderma Gangrenosum Associated with Hairy Cell Leukemia and Its Complete Response to Cladribine Therapy. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 273-275.	0.3	4
58	Hemophilia in the developing world: transforming lives through international collaboration. <i>Blood Advances</i> , 2018, 2, 39-41.	2.5	4
59	Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 672-673.	1.2	4
60	Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL. <i>Leukemia and Lymphoma</i> , 2021, 62, 1674-1681.	0.6	4
61	An unusual presentation of Richter's transformation of chronic lymphocytic leukemia in liver and lung on ¹⁸ F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography. <i>Indian Journal of Nuclear Medicine</i> , 2020, 35, 70.	0.1	4
62	Short Research Communication Anti-Spike Antibody Response to COVISHIELD [®] , [®] (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 745-749.	0.3	4
63	Outcomes of splenectomy versus cladribine for hairy cell leukemia in resource limited settings. <i>Leukemia and Lymphoma</i> , 2014, 55, 1428-1430.	0.6	3
64	CLL: Common Leukemia; Uncommon Presentations. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 268-275.	0.3	3
65	“Blueberry Muffin Spots” in an Adult Male Successfully Treated with Imatinib. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 174-175.	0.3	3
66	Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 114-118.	0.6	3
67	Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 313-317.	0.3	3
68	Role of pre-transplant chest high-resolution computed tomography and serum galactomannan index in predicting post-transplant invasive pulmonary aspergillosis in allogeneic hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13632.	0.7	3
69	Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort. <i>Annals of Hematology</i> , 2021, 100, 2031-2041.	0.8	3
70	Impact of broad-spectrum antibiotic exposures and multidrug-resistant gram-negative bacteremia on hematopoietic cell transplantation outcomes. <i>Transplant Infectious Disease</i> , 2021, 23, e13717.	0.7	3
71	CML patients presenting with priapism: Is there any disparity in outcome?. <i>Journal of Clinical Oncology</i> , 2019, 37, e18545-e18545.	0.8	3
72	Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramidate mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: A rapid and sensitive method development. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1198, 123228.	1.2	3

#	ARTICLE	IF	CITATIONS
73	Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2679-2685.	0.6	3
74	Acute promyelocytic leukaemia: looking through "gums". <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217457.	0.2	2
75	Fertility Management for the Hemato-Oncologist. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2018, 34, 13-18.	0.3	2
76	Variation in Adherence Measures to Imatinib Therapy. <i>Journal of Global Oncology</i> , 2018, 4, 1-10.	0.5	2
77	Goitre, lymphoma and the doughnut sign. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-226581.	0.2	2
78	Chronic Myeloid Leukemia Presenting with Fleeting Facial Nerve Palsy. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2019, 35, 371-372.	0.3	2
79	Waldenström Macroglobulinemia of the orbit: A diagnostic challenge. <i>European Journal of Ophthalmology</i> , 2020, , 112067212096345.	0.7	2
80	A systematic review of economic evaluations of treatment regimens in multiple myeloma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 21, 1-11.	0.7	2
81	Butter in blood: Hypertriglyceridemia secondary to pegylated. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 898-898.	0.2	2
82	Dose-adjusted EPOCH: a feasible alternative for Burkitt lymphoma in resource-constrained settings. <i>British Journal of Haematology</i> , 2020, 190, e362-e363.	1.2	2
83	Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience. <i>Blood Research</i> , 2021, 56, 134-140.	0.5	2
84	A quintessential syndrome with a rare marvellous aetiology: Rosai-Dorfman disease presenting as Conus-Cauda syndrome. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-222398.	0.2	2
85	Do Regulatory T Cells Have a Role in Disease Progression and Autoimmune Cytopenias of Chronic Lymphocytic Leukemia?. <i>Blood</i> , 2011, 118, 3864-3864.	0.6	2
86	Short Response Duration to Initial Treatment of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 5665-5665.	0.6	2
87	Methotrexate and mucositis: A merry-go-round for oncologists. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 150-152.	0.1	2
88	The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 157-162.	0.7	2
89	Successful Allogeneic Hematopoietic Cell Transplantation Using Flu-Bu-ATG Conditioning for "Mono-MAC Syndrome" [GATA2 Deficiency]. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S333.	2.0	1
90	Pre-Transplant Vitamin D Deficiency is Associated with Inferior Overall Survival but not Associated with Relapse Free Survival or Cumulative Incidence of GVHD Post Adult Hematopoietic Cell Transplantation for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S334.	2.0	1

#	ARTICLE	IF	CITATIONS
91	Use of Surrogate Samples to Monitor pH During High dose Methotrexate Therapy. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 188-194.	0.3	1
92	Balanitis in Acute Lymphoblastic Leukemia: A Rare Etiology and Unusual Presentation. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 546-548.	0.3	1
93	Diffuse Large B-Cell Lymphoma: A Rare Cause of Lung Consolidation. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 768-771.	0.3	1
94	Cost and complications are limitations in resource-constrained settings for equine anti-thymocyte globulin. European Journal of Haematology, 2018, 101, 421-421.	1.1	1
95	Haemorrhagic Bulla: A Rare Presentation of Acute Lymphoblastic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 369-370.	0.3	1
96	Intra-Abdominal Pseudotumors: A Rare Presentation of Von Willebrand Disease and its Management in Resource Constraint Setting. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 390-391.	0.3	1
97	Corpus Callosum Bleed: A Rare Presentation of Acute Promyelocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 384-386.	0.3	1
98	Multiple Granulocytic Sarcomas: A Rare Presentation of Acute Myeloid Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 186-188.	0.3	1
99	Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma. European Journal of Cancer, 2020, 136, 113-115.	1.3	1
100	Hematopoietic stem cell donor with IgA nephropathy: Challenges and management algorithm. Transfusion and Apheresis Science, 2020, 59, 102781.	0.5	1
101	Poor tolerability to ponatinib in Indian CML patients. Blood Advances, 2020, 4, 1927-1929.	2.5	1
102	Still learning the right way to administer melphalan in autologous transplantation. Bone Marrow Transplantation, 2020, 55, 2357-2358.	1.3	1
103	Caution: PET-CT in plasma cell disorders. Lancet Haematology, the, 2020, 7, e95.	2.2	1
104	Graft versus host disease localized to striae distensae: An example of locus minoris resistentiae. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 1-3.	0.2	1
105	The frequency and clinico-hematological characteristics of gain(1q21) positive myeloma in an Indian cohort. Leukemia Research, 2021, 105, 106577.	0.4	1
106	Infections Are a Major Cause of Prolongation of Hospital Stay in Hematopoietic Stem Cell Transplants in Tropical, Developing Countries: Profile of a Transplant Center in North India. Blood, 2014, 124, 5853-5853.	0.6	1
107	Outcome of CML patients with de novo bleeding complications: Do they behave differently?. Journal of Clinical Oncology, 2019, 37, e18546-e18546.	0.8	1
108	Deluging Thrombosis: An Unusual Presentation of Acute Promyelocytic Leukemia. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 282-284.	0.1	1

#	ARTICLE	IF	CITATIONS
109	Dual peaks on flow cytometric <scp>DNA</scp> ploidy analysis in chronic lymphocytic leukemia with <scp>Richter</scp> transformation. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 323-325.	0.7	1
110	Impact of bisphosphonate and anti-myeloma therapy on bone turnover markers in multiple myeloma. <i>Annals of Oncology</i> , 2018, 29, viii370.	0.6	0
111	A comparative study of 18F-FDG PET/CT with bilateral bone marrow trephine biopsy for assessment of bone marrow infiltration by lymphoma. <i>Annals of Oncology</i> , 2018, 29, viii362.	0.6	0
112	Assessment of bleeding risk by sonoclot in acute lymphoblastic leukemia. <i>Annals of Oncology</i> , 2018, 29, viii370.	0.6	0
113	An Unusual Case of Fungating Chest Wall Mass. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 211-212.	0.3	0
114	Resolution of high output pulmonary edema due to hyperviscosity with plasma exchange in a patient with multiple myeloma- a case report. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102898.	0.5	0
115	Does Mesenchymal Stromal Cell Count in Pre-autologous Hematopoietic Stem Cell Transplant Peripheral Blood and Apheresis Product Predict for Infectious Complications in the Post-transplant Period?. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 484-488.	0.3	0
116	Autosomal dominant familial periodic fever patient with a missense variant c.215G>A (p.Cys72Tyr) in TNFRSF1A gene presenting as neutrophilia. <i>European Journal of Medical Genetics</i> , 2021, 64, 104191.	0.7	0
117	Detection of c.755T>C; p.L265P/c.751C>T;p.264R/* compound heterozygous MYD88 mutation in a case of Waldenstrom macroglobulinemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2021, 37, 702-704.	0.3	0
118	Hematopoietic Stem Cell Applications: Past, Present and Future. <i>Journal of Postgraduate Medicine Education and Research</i> , 2012, 46, 69-74.	0.1	0
119	Real World Experience of Clinical Profile and Outcomes of Autoimmune Hemolytic Anemia: Single Centre Experience. <i>Blood</i> , 2016, 128, 4814-4814.	0.6	0
120	Individualized, Low Dose, Fixed Duration Lenalidomide Maintenance Is an Effective Strategy in High MRD Disease Post Chemo-Immunotherapy in CLL: Outcomes of a Randomized Controlled Trial. <i>Blood</i> , 2019, 134, 5471-5471.	0.6	0
121	A look inside the body of a BCR-ABL1-like acute lymphoblastic leukemia patient: the first case report highlighting the continued relevance of autopsy practice. <i>Blood Research</i> , 2021, , .	0.5	0
122	Clinical Research in Hematology&Oncology in India during the COVID-19 Era. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 799-800.	0.1	0
123	Covid-19 Infection in Hematological Malignancies: Registry Data from India. <i>Blood</i> , 2021, 138, 1938-1938.	0.6	0
124	Detection of Double Hit and Triple Hit Cytogenetics at Relapse Identifies a Very High Risk Subset of Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2021, 138, 2706-2706.	0.6	0